150 related articles for article (PubMed ID: 33801382)
1. In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor.
Montemagno C; Raes F; Ahmadi M; Bacot S; Debiossat M; Leenhardt J; Boutonnat J; Orlandi F; Barbato D; Tedesco M; Ghezzi C; Perret P; Broisat A
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801382
[TBL] [Abstract][Full Text] [Related]
2. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
3. The Balance Between the Therapeutic Efficacy and Safety of [
Verhoeven M; Haeck J; de Blois E; Orlandi F; Barbato D; Tedesco M; Konijnenberg M; Dalm SU
Mol Imaging Biol; 2024 Feb; 26(1):114-123. PubMed ID: 37640941
[TBL] [Abstract][Full Text] [Related]
4. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
Damiana TST; Paraïso P; de Ridder C; Stuurman D; Seimbille Y; Dalm SU
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3851-3861. PubMed ID: 37584725
[TBL] [Abstract][Full Text] [Related]
5. Safety of [
Ruigrok EAM; Verhoeven M; Konijnenberg MW; de Blois E; de Ridder CMA; Stuurman DC; Bertarione L; Rolfo K; de Jong M; Dalm SU
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4440-4451. PubMed ID: 35951084
[TBL] [Abstract][Full Text] [Related]
6. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
7. GMP-compliant production of [
Pretze M; Reffert L; Diehl S; Schönberg SO; Wängler C; Hohenberger P; Wängler B
EJNMMI Radiopharm Chem; 2021 Jul; 6(1):22. PubMed ID: 34228236
[TBL] [Abstract][Full Text] [Related]
8. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of
Gruber L; Jiménez-Franco LD; Decristoforo C; Uprimny C; Glatting G; Hohenberger P; Schoenberg SO; Reindl W; Orlandi F; Mariani M; Jaschke W; Virgolini I
J Nucl Med; 2020 Dec; 61(12):1749-1755. PubMed ID: 32332143
[TBL] [Abstract][Full Text] [Related]
9. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.
Verhoeven M; Ruigrok EAM; van Leenders GJLH; van den Brink L; Balcioglu HE; van Weerden WM; Dalm SU
Front Oncol; 2023; 13():1199432. PubMed ID: 37719014
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
11. Imaging Properties and Tumor Targeting of
Gruber L; Decristoforo C; Uprimny C; Hohenberger P; Schoenberg SO; Orlandi F; Mariani MF; Manzl C; Kasseroler MT; Tilg H; Zelger B; Jaschke WR; Virgolini IJ
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428467
[TBL] [Abstract][Full Text] [Related]
12. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
13. NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [
Kaloudi A; Lymperis E; Giarika A; Dalm S; Orlandi F; Barbato D; Tedesco M; Maina T; de Jong M; Nock BA
Molecules; 2017 Nov; 22(11):. PubMed ID: 29137110
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.
Lau J; Rousseau E; Zhang Z; Uribe CF; Kuo HT; Zeisler J; Zhang C; Kwon D; Lin KS; Bénard F
ACS Omega; 2019 Jan; 4(1):1470-1478. PubMed ID: 30775647
[TBL] [Abstract][Full Text] [Related]
16. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
18. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
19. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
20. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
